These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 9661172)
1. IGF in the clinic. Brower V Nat Biotechnol; 1998 Jul; 16(7):601-2. PubMed ID: 9661172 [No Abstract] [Full Text] [Related]
2. [Does insulin glargin (lantus) lead to a progression in diabetic retinopathy?]. Meyer CH; Kroll P; Hammes HP Klin Monbl Augenheilkd; 2005 Apr; 222(4):353-4. PubMed ID: 15844050 [No Abstract] [Full Text] [Related]
3. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates. Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235 [TBL] [Abstract][Full Text] [Related]
4. Cephalon adds to clinical disappointment in 1997. Glaser V Nat Biotechnol; 1997 Jun; 15(6):495-6. PubMed ID: 9181559 [No Abstract] [Full Text] [Related]
7. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process. Roden DM; Temple R Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869 [No Abstract] [Full Text] [Related]
8. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Clemmons DR Curr Opin Pharmacol; 2006 Dec; 6(6):620-5. PubMed ID: 17030015 [TBL] [Abstract][Full Text] [Related]
9. [Human insulin-like growth factor I and treatment in diabetes]. Koivisto VA Duodecim; 1994; 110(23-24):2197-201. PubMed ID: 8654239 [No Abstract] [Full Text] [Related]
10. To market, to market. The nuts and bolts of prescription drug approval. Peterson AM Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443 [No Abstract] [Full Text] [Related]
11. Drug safety. Gaps in the safety net. Couzin J Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480 [No Abstract] [Full Text] [Related]
12. Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. Christ ER; Carroll PV; Albany E; Umpleby AM; Lumb PJ; Wierzbicki AS; Sönksen PH; Russell-Jones DL Am J Physiol Endocrinol Metab; 2002 May; 282(5):E1154-62. PubMed ID: 11934682 [TBL] [Abstract][Full Text] [Related]
15. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes. Misbin RI Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753 [No Abstract] [Full Text] [Related]
17. [Growth hormone, insulin-like growth factor and insulin-like growth factor binding protein in young type I diabetes patients with the onset of diabetic angiopathy]. Peczyńska J; Urban M; Głowińska B; Urban B Pol Merkur Lekarski; 2003 Apr; 14(82):336-9. PubMed ID: 12868196 [TBL] [Abstract][Full Text] [Related]
18. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move. Moss RW New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956 [No Abstract] [Full Text] [Related]
19. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process. Binzak BA Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592 [No Abstract] [Full Text] [Related]
20. [Novo Nordisk introduces a new basic insulin for marketing]. Krankenpfl J; 2004; 42(5-6):168-9. PubMed ID: 15527230 [No Abstract] [Full Text] [Related] [Next] [New Search]